Buy & Sell VICI Properties Inc (VICI) – VICI Properties Inc Price Today
Aura AI Summary
Key Stats
- $30.00BMarket Cap
- Real EstateSector
- -9.8%3M Drawdown
- $47.22BEnterprise Value
- 6.46%Dividend Yield
- 23 daysTypical Hold Time
VICI Properties Inc (VICI) is currently valued at a market capitalization of $30.00B, with an enterprise value of $47.22B. Over the past 52 weeks, VICI Properties Inc has traded between a low of $26.61 and a high of $33.93, highlighting its annual price range. Over the past three months, VICI Properties Inc has recorded a drawdown of -9.8%, reflecting recent price volatility. VICI Properties Inc offers a dividend yield of 6.46%, with the most recent dividend of $0.45 paid on 19 Mar 26. On average, investors hold VICI Properties Inc for approximately 23 days, indicating typical investor behavior on the platform.
About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Most Recent News
Digital Realty launches Malaysia data center operations to boost Southeast Asia's digital and AI infrastructure.
Digital Realty has officially launched its Malaysia operations with a new data center campus in Cyberjaya, aiming to expand its capacity to 32 MW. This development integrates Malaysia into Digital Realty's global network, supporting AI and data-drive...

Willis expands international property insurance facility to offer up to $60M per placement.
Willis Towers Watson has increased the capacity of its international property insurance facility to provide up to $60 million of follow capacity per placement. This expansion includes a broader panel of Lloyd’s syndicates and enhanced support from Wi...

FDA accepts Alvotech's application for AVT16, a biosimilar to Entyvio, advancing treatment options for inflammatory diseases.
Alvotech announced that the FDA has accepted its Biologics License Application for AVT16, an interchangeable biosimilar to Entyvio (vedolizumab), used to treat ulcerative colitis and Crohn’s disease. This acceptance marks a key step toward expanding ...
